Drugs / 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
last change Jun 2025 re-read 2 minutes ago

13-valent pneumococcal conjugate vaccine (multivalent conjugate)

Vaccine

Developed for
pneumococcal infection
Investigated by
Fosun Adgenvax Biopharmaceutical Co.,Ltd.

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05759520 Nov 2022 → Jun 2025 overdue pneumococcal infection Fosun Adgenvax Biopharmaceutical Co.,Ltd. Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 13-valent pneumococcal conjugate vaccine (multivalent conjugate) ClinicalTrials.gov intervention name — accepted as the source's own label NCT05759520
Modality Vaccine “13-valent pneumococcal conjugate vaccine (multivalent conjugate)” NCT05759520